Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 72338-100

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 72338-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Waverley Pharma Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Carton – Pemetrexed For Injection 100 mg Single-dose Vial (Pemetrexed 100mg Carton Trade)

Label for Pemetrexed For Injection, USP 100 mg single-dose vial by Waverley Pharma. It is a lyophilized powder for intravenous use. The label includes storage instructions, reconstitution guidance, and a caution noting the product is cytotoxic. Distributed by Medicure Pharma, Inc. and made in India.*

FDA Label Image

Package Carton – Pemetrexed For Injection 100 mg Single-dose Vial (Pemetrexed 100mg Label)

Label for Pemetrexed for Injection, USP 100 mg vial, lyophilized powder for intravenous use. The label includes caution for cytotoxic agent, storage instructions, and distributor information for Medicure Pharma, Inc. Barcode and product NDC 72338-100-01 are visible. Labeler is Waverley Pharma Inc.*

FDA Label Image

Package Carton – Pemetrexed For Injection 500 mg Single-dose Vial (Pemetrexed 500mg Carton Trade)

Pemetrexed For Injection, USP 500 mg single-dose vial label. Powder, lyophilized for intravenous use only, supplied by Waverley Pharma Inc. The label includes storage instructions, reconstitution directions using 0.9% Sodium Chloride Injection, and product warnings. Distributed by Medicure Pharma, Inc., made in India. Barcode and NDC 72338-101-01 also shown.*

FDA Label Image

Package Label – Pemetrexed For Injection 500 mg Single-dose Vial (Pemetrexed 500mg Label)

Label for Pemetrexed for Injection, USP 500 mg single-dose vial, lyophilized powder for intravenous use. The label includes storage instructions and a caution that it is a cytotoxic agent. Manufactured by Waverley Pharma Inc. and distributed by Medicure Pharma, Inc. Barcode and serialization mark are also visible.*

FDA Label Image

Structural Formula (Pemetrexed F01 V01)

Chemical structure of pemetrexed disodium, showing its molecular arrangement including two sodium ions and associated water of crystallization (2.5 H2O).*

FDA Label Image

Figure 1 (Pemetrexed F01)

A Kaplan-Meier survival curve showing overall survival percentages over time in months for two treatment arms labeled A+P+C and A+C. The vertical axis represents overall survival (%) from 0 to 100, and the horizontal axis represents time in months from 0 to 21. The chart includes a table of numbers at risk at various months for each treatment arm.*

FDA Label Image

Figure 2 (Pemetrexed F05 V04)

A survival analysis Kaplan-Meier curve comparing survival probability over time (months) for two chemotherapy regimens: Pemetrexed + Cisplatin (solid line) and Gemcitabine + Cisplatin (dotted line). The chart includes patient numbers at risk at specific time intervals up to 30 months.*

FDA Label Image

Figure 3 (Pemetrexed F08 V3)

A Kaplan-Meier survival curve comparing the survival probability over 30 months for two treatment groups: Pemetrexed plus Cisplatin (solid line) and Gemcitabine plus Cisplatin (dotted line). The x-axis represents survival time in months, and the y-axis shows survival probability from 0 to 1. Patient counts at various time points are listed below.*

FDA Label Image

Figure5 (Pemetrexed F12 V3)

A Kaplan-Meier survival curve depicting survival probability over time in months for two groups: Pemetrexed (solid line) and Placebo (dotted line). The chart includes a table below showing the number of patients at risk at various time points up to 42 months.*

FDA Label Image

Figure 6 (Pemetrexed F13 V2)

A Kaplan-Meier survival curve comparing survival probability over time in months between patients treated with Pemetrexed and placebo. The solid line represents Pemetrexed, showing higher survival probability than the dotted line representing placebo. Below the x-axis is a table of patients at risk for each group at various time points up to 42 months.*

FDA Label Image

Figure 8 (Pemetrexed F14 V2)

A Kaplan-Meier survival curve comparing survival probability over time (in months) between Pemetrexed and placebo groups. The solid line represents Pemetrexed and the dotted line placebo. Below the graph, the number of patients at risk at various time points is listed for each group.*

FDA Label Image

Figure 4 (Pemetrexed F15 V01)

A survival probability Kaplan-Meier plot comparing two chemotherapy regimens: Pemetrexed plus Cisplatin (AC) and Gemcitabine plus Cisplatin (GC) over a 30-month period. The x-axis represents survival time in months; the y-axis represents survival probability from 0 to 1. Patient numbers at risk are listed below the graph for each time point up to 28 months.*

FDA Label Image

Figure 7 (Pemetrexed F16 V1)

A Kaplan-Meier survival curve chart comparing survival probability over months between Pemetrexed and Placebo groups. The x-axis represents survival time in months from 0 to 42, and the y-axis shows survival probability from 0 to 1. A solid line represents Pemetrexed, and a dotted line represents Placebo. A table below lists patients at risk at various time points for both groups.*

FDA Label Image

Figure 8 (Pemetrexed F17 V1)

A Kaplan-Meier survival curve comparing survival probability over months between patients treated with Pemetrexed plus Cisplatin and those treated with Cisplatin alone. The graph includes two lines with survival probabilities on the vertical axis and survival time in months on the horizontal axis. Patient numbers at risk for each group are listed below the graph.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.